The REWIND trial mainly assessed the cardiovascular outcomes of dulaglutide over up to 8 years
47 The efficacy and safety of resmetirom are currently being studied in a phase III RCT (MAESTRO-NASH) in stage 23 fibrosis NASH patients (NCT03900429)
It would be helpful to look at any effects on healthy individuals taking semaglutide
These factors underscore the importance of individualized assessment and consultation with a healthcare professional to determine the optimal amount for each patient
All of these diets have the capacity to exert a beneficial influence on metabolic parameters, such as blood pressure, glycemia, and lipid levels, in addition to weight loss [2, 5,6,7,8,9,10,11,12]